KORU Medical Systems
Logotype for KORU Medical Systems Inc

KORU Medical Systems (KRMD) investor relations material

KORU Medical Systems Corporate presentation summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for KORU Medical Systems Inc
Corporate presentation summary16 Nov, 2026

Business and platform

  • Enables large-volume subcutaneous drug delivery at home and in clinics, supporting the shift from hospital-based IV therapy to patient-administered care.

  • Freedom Infusion System serves ~60,000 chronic patients and supports ~2.7M annual recurring infusions; weekly SCIg treatment is typically ongoing for chronic conditions.

  • Seven SCIg drugs from four major pharmaceutical manufacturers are cleared for use; Freedom60 and FreedomEDGE also have 510(k) clearance and MDR approval for prefilled syringes.

  • Product mix is ~20% mechanical pumps and ~80% customizable consumables; cited patient adherence rate is 97%.

Market opportunity and pipeline

  • Large-volume SC opportunity includes a growing SCIg market with <20% penetration versus IVIg, plus 95+ drugs in development at volumes above 10 mL.

  • Estimated market opportunity is ~$60M in 2025 and ~$138M by 2030; 13 drugs launched during 2020–2026, diversifying the market mainly into oncology.

  • Pipeline includes eight active new-drug or indication opportunities and nine drugs on the system label; estimated annual infusion volumes include 5.4M for SCIg and <0.25M for non-SCIg drugs.

  • Near-term opportunities include deferoxamine, Phesgo, Empaveli for FSGS and DGF, and enzyme therapy; estimated launch windows span 0–1, 1–3 and 3–5 years.

Financial performance

  • FY2025 revenue was $41.1M; FY2026 guidance is $48M–$48.5M, 17–18% YoY growth, 63–64% gross margin, positive adjusted EBITDA and year-end cash above $8M.

  • YTD 2026 revenue was $35.4M, up 17%; gross margin was 64.0%, up 190 bps, and operating expenses were 64.1% of sales, a 620 bps improvement YoY.

  • YTD 2026 net loss was $0.3M versus $2.2M; adjusted EBITDA was $2.2M versus $0.1M, while cash usage was $1.5M and included a ~$1M Q2 technology acquisition.

  • Long-term goals include $100M revenue, accelerated double-digit revenue CAGR, gross margin above 65% and EBITDA margin above 20%.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next KORU Medical Systems earnings date

Logotype for KORU Medical Systems Inc
38th Annual Healthcare Conference1 Dec, 2026
KORU Medical Systems
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next KORU Medical Systems earnings date

Logotype for KORU Medical Systems Inc
38th Annual Healthcare Conference1 Dec, 2026

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

KORU Medical Systems Inc. specializes in developing and manufacturing medical devices for subcutaneous drug delivery. The company’s primary products include infusion systems designed for use in home and alternate care settings, offering patients a convenient and effective way to administer biologics and other medications. KORU Medical serves the pharmaceutical and biotechnology industries, providing solutions that support patient-centric care. The company is headquartered in Mahwah, New Jersey, and its shares are listed on the NASDAQ.